Alpenglow Biosciences
Alpenglow Biosciences digitizes intact tissue samples into quantitative 3D datasets to improve spatial biology research and clinical diagnostics. The company’s Aurora 3D Spatial Biology Platform combines light-sheet microscopy for nondestructive, subcellular 3D imaging with proprietary chemistry and cloud-based AI and bioinformatics (3D*i™, 3D*m™, 3D*ai*) for automated data management and analysis. The offering is delivered as a B2B SaaS solution with instrumentized imaging, AI models, and integrations for laboratory workflows and downstream molecular assays. Typical customers are pharmaceutical and biotechnology researchers using the platform for preclinical discovery, immuno-oncology, and dermatology assays. Alpenglow partners with major pharma companies and holds government research contracts, positioning it for adoption across drug development and clinical research pipelines.
Alpenglow Biosciences
Alpenglow Biosciences digitizes intact tissue samples into quantitative 3D datasets to improve spatial biology research and clinical diagnostics. The company’s Aurora 3D Spatial Biology Platform combines light-sheet microscopy for nondestructive, subcellular 3D imaging with proprietary chemistry and cloud-based AI and bioinformatics (3D*i™, 3D*m™, 3D*ai*) for automated data management and analysis. The offering is delivered as a B2B SaaS solution with instrumentized imaging, AI models, and integrations for laboratory workflows and downstream molecular assays. Typical customers are pharmaceutical and biotechnology researchers using the platform for preclinical discovery, immuno-oncology, and dermatology assays. Alpenglow partners with major pharma companies and holds government research contracts, positioning it for adoption across drug development and clinical research pipelines.
TL;DR
Core offering: Aurora 3D Spatial Biology Platform combining open-top light-sheet microscopy, data management, and AI analysis
Customers: Pharmaceutical and biotechnology researchers (preclinical discovery, immuno‑oncology, dermatology)
Founded: 2018
Recent funding signal: Government grants/contracts (NIH, ARPA‑H) and venture rounds including Dynamk Capital
Related Companies
| Company |
|---|
 |
 |
 |
 |
 |